Clinical Trial Update: Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors [Phase 1]

View source ↗

Summary

A Phase I trial evaluates the safety and pharmacokinetics of oral 14C-AZD2171 (cediranib) in patients with advanced solid metastatic tumors; the study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Cediranib (Cediranib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Solid Metastatic Tumor | Phase 1 | Status: COMPLETED